Newer Drug Options for Hypertrophic Cardiomyopathy
Cardiac myosin inhibitors (specifically mavacamten) represent the most significant new drug class for HCM, now recommended as first-line escalation therapy alongside disopyramide and septal reduction for symptomatic obstructive HCM patients who fail beta-blockers or calcium channel blockers. 1
The Breakthrough: Cardiac Myosin Inhibitors
Mavacamten - The First FDA-Approved Cardiac Myosin Inhibitor
Mavacamten directly targets the underlying pathophysiology of HCM by inhibiting actin-myosin cross-bridge formation, reducing the hypercontractility that defines this disease 1, 2. This represents a paradigm shift from traditional therapies that only provided symptomatic relief without addressing the molecular mechanism.
Clinical efficacy data:
- Improves LVOT gradients, symptoms, and functional capacity in 30-60% of patients with obstructive HCM 1
- The 2024 AHA/ACC guidelines now give it a Class 1 recommendation for adults with persistent symptoms despite first-line therapy 1
Critical Safety Considerations for Mavacamten
Mandatory echocardiographic surveillance is required due to risk of excessive LVEF reduction:
- Monthly echocardiograms for the first 3 months, then every 3 months thereafter 2
- Do not initiate if LVEF <55% 2
- Temporarily discontinue if LVEF drops <50% during follow-up 2
- Permanently discontinue if LVEF <30% 2
- 5.7% of patients experience LVEF reduction <50% attributable to the drug alone, but up to 7-10% when considering other clinical conditions 1
Mavacamten is absolutely contraindicated in pregnancy due to teratogenic potential 1, 3. Women of childbearing age require effective contraception during treatment and for at least 4 months after discontinuation 2.
Treatment Algorithm for Obstructive HCM
First-Line Therapy
- Beta-blockers (nonvasodilating types) - titrate to resting heart rate suppression, not just symptom response 1
- Alternative: Nondihydropyridine calcium channel blockers (verapamil or diltiazem) if beta-blockers are ineffective or not tolerated 1
Avoid carvedilol and labetalol - their vasodilatory properties can worsen outflow obstruction 2
Second-Line/Escalation Therapy (Class 1 Recommendation)
When first-line therapy fails, you have three equally recommended options 1:
- Add mavacamten (adults only)
- Add disopyramide (must combine with AV nodal blocking agent to prevent rapid ventricular response in atrial fibrillation) 1
- Septal reduction therapy at experienced comprehensive HCM centers
The choice among these three options requires shared decision-making discussing success rates, benefits, and risks specific to each patient 1.
Emerging Therapies on the Horizon
Aficamten - Second Cardiac Myosin Inhibitor
Currently in Phase III trials with promising data, representing the next generation of this drug class 4, 5
For Nonobstructive HCM
Valsartan may be beneficial (Class 2b recommendation) for younger patients (≤45 years) with nonobstructive HCM, pathogenic sarcomere variants, and mild phenotype to slow adverse cardiac remodeling 1, 3
Future Directions
- Next-generation myosin modulators 6, 7
- SGLT2 inhibitors showing promise through improved myocardial energetics 7
- Gene-targeted therapies under investigation 7
Critical Pitfalls to Avoid
Medications that worsen LVOTO must be discontinued:
- Pure vasodilators (ACE inhibitors, ARBs, dihydropyridine calcium channel blockers) 1
- Digoxin 1
- High-dose diuretics (low-dose may be cautiously used for persistent congestion) 1
Never use disopyramide as monotherapy - it enhances AV nodal conduction and can cause dangerous rapid ventricular rates if atrial fibrillation develops 1, 8, 1
In patients who develop systolic dysfunction (LVEF <50%), cardiac myosin inhibitors must be discontinued immediately 1, 3
Key Distinction from 2011 Guidelines
The 2024 guidelines 1 represent a major update from the 2011 recommendations 8, 9, which only included beta-blockers, calcium channel blockers, and disopyramide. Mavacamten's addition as a Class 1 recommendation for escalation therapy is the most significant pharmacologic advance in HCM treatment in over a decade, offering the first disease-modifying therapy that directly targets sarcomeric hypercontractility rather than just managing symptoms.